Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S). and BÜCHI Labortechnik AG, both leaders in cannabis production and processing services. About Valcon Medical.

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

Cannabis Law Report

JULY 29, 2021

This initial export to Austria marks Avicanna’s first commercial export of psychoactive THC Cannabis Extracts into the emerging European medicinal cannabis market. Initial shipment of THC extracts into the European Union.

Extraction 98

Extraction Supply Chain THC Research and Development 98

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52

Cannabis Law Report

JUNE 1, 2022

Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients. Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

JANUARY 19, 2022

(ASX: LGP) (“LGP”), a vertically integrated cannabis manufacturer, that AMP has been appointed as marketer and distributor of LGP medical cannabis extracts to pharmacies and clinics in Germany , including exclusive distributor of LGP’s 20:5 LGP Classic and 10:10 LGP Classic extract oils. ” Ms.

Extraction 52

Extraction Oil Research and Development Medicine 52

Cannabis Law Report

APRIL 2, 2023

Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has successfully […]

Extraction 52

Extraction Pharmaceutical Patients Business 52

Canna Care Docs

OCTOBER 3, 2023

On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

AUGUST 18, 2021

Seed confirmed on Tuesday that Eurox had successfully launched its own “unique” brand of ‘made in Germany’ full-spectrum medical cannabis extracts, representing a milestone for the company, with products now available for German pharmacies to order. Seed has an 8.85% shareholding in Eurox.

Extraction 105

Extraction Pharmaceutical THC Patients 105

FloridaMarijuana.net

AUGUST 16, 2018

Dementia cannot be confirmed until a patient is deceased. Dementia is hard on the patient, and often harder on the family or caregivers. Pharmaceutical treatments for for Dementia often only target symptoms like pain or depression, but those medicines do not cure or prevent the disease. 9-tetrahydrocannabinol (?

Clinical Trials 184

Clinical Trials Marijuana Patients Pharmaceutical 184

Cannabis Law Report

JULY 21, 2019

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). (CSE: WRLD.U)(FWB:

Pharmaceutical 40

Pharmaceutical THC CBD Supply Chain 40

Cannabis Law Report

JULY 19, 2019

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). (CSE: WRLD.U)(FWB:

Pharmaceutical 40

Pharmaceutical THC CBD Supply Chain 40

Cannabis Law Report

NOVEMBER 17, 2021

. (“ZYUS”), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that the company has launched a new THC-dominant medical cannabinoid formulation, Zylem™ 20:1, for direct sales and distribution to registered medical patients across Canada.

Cannabinoids 52

Cannabinoids Patients Research and Development Extraction 52

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

SEPTEMBER 14, 2021

Join Us in Advancing Cannabis Science to Elevate the Industry , by Pelin Thorogood, Co-founder and Executive Chair of Radicle Science, and Nicole Brown, Chief Innovation Officer of Open Book Extracts. About Open Book Extracts. About Radicle Science. To learn more, please visit www.radiclescience.com and follow their LinkedIn page.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

FEBRUARY 1, 2022

New softgel capsule products further expand ZYUS’ medical cannabinoid offerings and provide patients a precise method for dosing. The two Zylem™ Softgel Capsule products each have their own unique colour to provide patients with an easy way to identify and distinguish between ZYUS softgel capsule formulations.

Cannabinoids 52

Cannabinoids Patients Research and Development Media 52

Cannabis Law Report

JULY 2, 2021

CannaVerde Pharma is a vertically integrated medical cannabis company with core operations in Colombia, focused on delivering low-cost, pharmaceutical grade, EU-GMP compliant cannabis-based products to consumers and medical patients in Latin America and Europe. Company Overview. High Margin Revenue Streams. Full Suite of Licenses.

Sleep 105

Sleep Pharmaceutical THC Extraction 105

Greencamp

MAY 1, 2019

Since then, countless patients found relief in cannabis, even though most of the times doctors would only recommend it when all other “mainstream” options were exhausted. However, some people don’t react well to antiemetics—most notably cancer patients going through aggressive chemo. And that’s where cannabis comes into play.

Patients 89

Patients Strains Sativa Marijuana 89

Project CBD

MARCH 8, 2019

For years, hemp companies have been producing CBD rich extracts and marketing them for animals and humans. Immediately in response, the FDA announced that CBD is considered a “drug” and is thus subject to pharmaceutical regulations. In response, veterinarians and others concerned for patient safety promoted a change in state law.

Pets 215

Pets Legalization Hemp Extraction 215

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! In fact, there are some patients who prefer not to smoke because of their health conditions or other reasons. Myth: Cannabis is a cure-all.

Research and Development 108

Research and Development Indica Treatment Conditions 108

Canna Care Docs

JUNE 22, 2018

An Introductory Lesson on THC Basics For Medical Cannabis Patients. Cannabis, a plant that has proven to be endlessly complex is still under the microscope by researchers, patients, physicians, and society. But many new patients need an introduction on THC basics, learning how it plays a role in a patient’s well-being and healing.

THC 66

THC Patients Blood Pressure Clinical Trials 66

Cannabis Law Report

APRIL 29, 2022

LONDON, April 29, 2022 –( BUSINESS WIRE )–Curaleaf International (the “Company”) part of Curaleaf Holdings (CNSX:CURA), Europe’s largest vertically integrated cannabis company, is pleased to announce the successful license of the Company’s range of cannabis based medicines as extract, under the name Adven, in Malta.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Patients 52

Cannabis Law Report

OCTOBER 26, 2021

Following this selection, Tilray will supply a variety of its pharmaceutical-grade medical cannabis products, including extracts and dried flower with different degrees of THC and CBD for patients with varying medical conditions.

Pharmaceutical 52

Pharmaceutical Research and Development Patients Access 52

FloridaMarijuana.net

AUGUST 15, 2018

Most commonly, patients report that tingling and numbness occur, usually in the hands and feet. Six trials that included 325 patients examined chronic pain, 6 trials that included 396 patients investigated neuropathic pain, and 12 trials that included 1600 patients focused on multiple sclerosis.

Chronic Pain 150

Chronic Pain Marijuana Patients Clinical Trials 150

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

United Patients Group

FEBRUARY 7, 2023

Cannabis is an effective treatment for pain and inflammation Cannabis is a natural alternative to pharmaceutical drugs. The most effective way depends on the patient’s condition and overall health status but generally speaking most people prefer inhalation over other methods because it delivers relief quickly (within minutes).

Cannabinoids 114

Cannabinoids Chronic Pain Terpenes THC 114

Cannabis Law Report

APRIL 29, 2022

German patients can now buy high-THC, British Columbia-grown pot products at their local pharmacies. On Tuesday, the European medical pot firm Cantourage GmbH announced a partnership with Canadian licensed producer Miracle Valley Medicinal Alternatives Inc. to start offering its Mac 1 cultivar products to German pharmacies.

Pharmaceutical 59

Pharmaceutical Cultivation Extraction Patients 59

MMJ Recs

APRIL 1, 2024

Its non-addictive nature and minimal side effects make it an attractive alternative to conventional pharmaceuticals for many individuals seeking natural remedies. By promoting relaxation and reducing anxiety, CBD may help individuals achieve restful sleep without the need for pharmaceutical interventions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

SpeedWeed

SEPTEMBER 9, 2021

In fact, the pharmaceutical infrastructure that faces medical cannabis companies is far from either clear cut or easy to navigate. for example), pharmaceutical drugs may not be advertised directly to potential consumers (also known as patients). The Future of Generic Extracts. Here is why. Unlike the U.S.

Legalization 52

Legalization Pharmaceutical Patients Extraction 52

Cannabis Law Report

MAY 29, 2019

The research will focus on the optimisation of breeding and cultivating processes and the extraction of material to assess their efficacy of medical cannabis on prostate, melanoma and other cancer cells. Here’s the press release. All intellectual property from the trials will be owned by MGC, which is funding the research.

Cultivation 40

Cultivation Pharmaceutical Clinical Trials Extraction 40

MedicalJane

MAY 21, 2020

The UNM researchers set out to examine the effectiveness of consuming “legal” hemp oil extracted from the whole Cannabis plant. A chronic neuropathic pain model was used that exposed mice to post-operative neuropathic pain equivalent to several years of chronic pain in human patients. Westlund, Department of Anesthesiology.

Oil 100

Oil Hemp Extraction Clinical Trials 100

United Patients Group

FEBRUARY 2, 2023

There are also other parts of the plant with different uses such as seeds which can be eaten like nuts; stems/leaves which can be cooked into tea; resins/oils which can be ingested thru various methods including capsules, tinctures & edibles; and finally extracts which come from isolating specific compounds found within whole plants.

Blood Pressure 103

Blood Pressure Sleep Chronic Pain Digestion 103

Veriheal

JANUARY 25, 2022

Patients have expressed their disappointment with quality and pricing, citing the black market or other legal states as much better alternatives. The statement confirms that the farm bill did not legalize products made with CBD extracted from hemp. A theory towards a solution would be for all hemp extracts to be approved by the FDA.

Hemp 98

Hemp Business CBD Seed-To-Sale 98

The Cannigma

DECEMBER 4, 2022

Patients can be prescribed medical marijuana in the form of pharmaceuticals, like Sativex. However, this legalization is a technicality, as there is no established medical program for patients to join. Romania technically legalized medical cannabis back in 2013. CBD regulations.

Law 59

Law Seed-To-Sale Programs Tincture 59

Canna Care Docs

SEPTEMBER 18, 2020

Patients under the age of 18 must also have a parent or guardian registered as a caregiver on their behalf. Patients may purchase a 90 day supply of their medication. Patients may purchase medical cannabis in oil-based preparations such as lozenges, capsules, and vape pens. Can a Qualifying Patient Grow Cannabis in Virginia?

Pharmaceutical 98

Pharmaceutical Conditions Patients Oil 98

SpeedWeed

MARCH 9, 2021

ONE of Germany’s largest pharmaceutical firms has entered the medical cannabis space with the launch of a two flower products – and six more products to follow. Hesse-based Stada, Germany’s fifth largest pharmaceutical company, announced late last year it had entered into an agreement with Canadian firm MediPharm Labs.

Chronic Pain 52

Chronic Pain Business Pharmaceutical Extraction 52

MJ Business Attorneys

JUNE 29, 2018

Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

Veriheal

FEBRUARY 1, 2022

A Look Into Dystonia Patients and Cannabis. The team of researchers’ objective was to assess the effect of medical cannabis on patients with dystonia since it was suggested as a treatment for involuntary contractions of muscles in several case reports and case series. Cannabis Improves Quality of Life for Dystonia Patients.

Treatment 98

Treatment Patients Cannabis Oil 98